It refers to methods that resupply ATP or an equivalent high-energy cofactor inside a cell-free reaction, typically by adding substrates or enzyme cascades to the lysate rather than relying on a living cell's metabolism. Without it, translation or biosynthesis reactions in a lysate stall within hours because the cofactor pool is not replenished. This dataset specifically isolates patent records claiming that regeneration step, rather than cell-free technology in general, which is why the record count (53) is smaller than a general cell-free search would return.

The assignee ranking supplied with this dataset covers 10 companies and research institutions, with the leader holding 26 of the records and the tenth-ranked entity holding just 1. That is a steep drop-off rather than a gradual one, meaning a small number of organisations account for most of the sustained filing activity while the rest appear as single or occasional filers. Because the ranking counts records rather than a fixed top-50 or top-100 cut, it should be read as the complete set the data endpoint returns, not a sample.

Filing peaked at 19 records in 2018 after starting at 9 in 2017, and the tracked 2021-to-2024 window shows a -100% change. However, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in this dataset are still filling in and should not be read as evidence of a continuing decline. A fair reading is that the field cooled after its 2018 peak, with the most recent trend still uncertain until later publications catch up.

C12N, covering microorganisms and genetic engineering, appears in 69.8% of the 53 records in scope, and C12P, covering fermentation and enzymatic synthesis, appears in 64.2%. Bioreactor and enzyme apparatus claims under C12M appear in only 15.1%, and measuring or testing claims under C12Q in 17.0%. Because a single record can carry multiple IPC classes, these shares add up to more than 100%, and the pattern shows claim density sitting mostly on the biochemistry side rather than on equipment design.

This INSERM-filed record, published 2015-12-31, claims a cell-free translation system built on a ribosome-depleted red blood cell lysate combined with ribosomes isolated separately from eukaryotic cells, subject to specific provisos on which lysate and ribosome sources may be paired. It is cited 14 times within this corpus, making it one of the more referenced records in the field. Anyone building a red-blood-cell-lysate translation system should check whether their ribosome source and lysate-treatment combination falls inside those provisos before assuming a clear path.